Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
MARKETS
AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement
By Amanda Albright
Dec 21, 2015 10:09 AM EST
PRESS RELEASES
AVEO Oncology Announces Results From Phase 1b Portion Of DEDUCTIVE Study Of Tivozanib (FOTIVDA®) In Combination With IMFINZI® (durvalumab) In Previously Untreated Metastatic Hepatocellular Carcinoma
By Business Wire
Jan 15, 2021 8:00 AM EST
PRESS RELEASES
AVEO Oncology Announces Participation At Two Upcoming Investor Conferences
By Business Wire
Jan 6, 2021 7:00 AM EST
PRESS RELEASES
AVEO Oncology Announces Webcast Of Presentation At The 39th Annual J.P. Morgan Healthcare Conference
By Business Wire
Jan 5, 2021 7:00 AM EST
PRESS RELEASES
AVEO Oncology To Present At The Stifel 2020 Virtual Healthcare Conference
By Business Wire
Nov 10, 2020 7:00 AM EST
PRESS RELEASES
AVEO Oncology And EUSA Pharma Announce Annals Of Oncology Publication Of Data From Phase 1b/2 TiNivo Study In Renal Cell Carcinoma
By Business Wire
Nov 5, 2020 7:00 AM EST
PRESS RELEASES
AVEO Oncology Announces European Urology Publication Of Final Overall Survival Data From Phase 3 TIVO-3 Study Of Tivozanib In Renal Cell Carcinoma
By Business Wire
Sep 15, 2020 4:05 PM EDT
PRESS RELEASES
AVEO Oncology Regains Full Global Rights To Ficlatuzumab
By Business Wire
Sep 8, 2020 7:00 AM EDT
PRESS RELEASES
AVEO Oncology Announces Participation At Two Upcoming Investor Conferences
By Business Wire
Sep 3, 2020 7:00 AM EDT
PRESS RELEASES
AVEO Oncology Announces Restructuring Of Existing Term Loan With Closing Of New Tranched, $35 Million Debt Facility
By Business Wire
Aug 10, 2020 4:05 PM EDT
PRESS RELEASES
AVEO Oncology Announces $2.8M Development Milestone Earned From Kyowa Kirin
By Business Wire
Aug 5, 2020 4:05 PM EDT
PRESS RELEASES
AVEO Announces Closing Of Public Offering Of Common Stock And Partial Exercise Of Option To Purchase Additional Shares
By Business Wire
Jun 19, 2020 4:05 PM EDT
PRESS RELEASES
AVEO Announces Pricing Of $44.6 Million Public Offering Of Common Stock
By Business Wire
Jun 16, 2020 10:38 PM EDT
PRESS RELEASES
AVEO Announces Proposed Public Offering Of Common Stock
By Business Wire
Jun 15, 2020 4:05 PM EDT
PRESS RELEASES
AVEO Oncology Announces FDA Acceptance For Filing Of A New Drug Application For Tivozanib As A Treatment Of Relapsed Or Refractory Renal Cell Carcinoma
By Business Wire
Jun 1, 2020 1:15 PM EDT
PRESS RELEASES
AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study Of FOTIVDA® (tivozanib) In Combination With IMFINZI® (durvalumab) In Previously Untreated Metastatic Hepatocellular Carcinoma Advances To Phase 2
By Business Wire
May 29, 2020 7:05 AM EDT
PRESS RELEASES
AVEO Oncology Announces TIVO-3 Final Overall Survival Results Featured At ASCO 2020 Virtual Scientific Program And Submitted To U.S. FDA As Part Of NDA Filing
By Business Wire
May 29, 2020 7:00 AM EDT
PRESS RELEASES
AVEO Announces Change To Virtual Annual Meeting Of Stockholders
By Business Wire
May 27, 2020 4:05 PM EDT
PRESS RELEASES
AVEO Oncology To Present Final Overall Survival Analysis From The Phase 3 TIVO-3 Trial Of Tivozanib In Renal Cell Carcinoma At The ASCO 2020 Virtual Scientific Program
By Business Wire
Apr 29, 2020 2:30 PM EDT
PRESS RELEASES
AVEO Oncology Announces Submission Of New Drug Application To U.S. FDA For Tivozanib In Patients With Relapsed Or Refractory Renal Cell Carcinoma
By Business Wire
Mar 31, 2020 4:05 PM EDT
PRESS RELEASES
AVEO Oncology And Biodesix To Discontinue CyFi-2 Study Of Ficlatuzumab In Relapsed And Refractory AML In Response To Public Health Crisis
By Business Wire
Mar 27, 2020 4:40 PM EDT
PRESS RELEASES
AVEO Announces Effectiveness Of 1-for-10 Reverse Stock Split
By Business Wire
Feb 19, 2020 9:08 AM EST
PRESS RELEASES
AVEO Oncology Announces Publication Of Phase 1b/2 Study Of Tivozanib In Advanced, Inoperable Liver Cancer In The British Journal Of Cancer
By Business Wire
Feb 12, 2020 4:26 PM EST
PRESS RELEASES
AVEO Oncology And Biodesix Announce Results From Phase 1b Study Of Ficlatuzumab, Gemcitabine And Nab-paclitaxel In Advanced Pancreatic Cancer
By Business Wire
Jan 27, 2020 7:00 AM EST
MARKETS
AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement
By Amanda Albright
Dec 21, 2015 10:09 AM EST
